35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
45 citations
,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
August 2020 in “European Journal of Dermatology” Dutasteride for hair loss can cause skin reactions like itchy red plaques.
January 2020 in “대한피부과학회지” Dutasteride effectively increases hair density in women with hair loss.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
June 2024 in “Journal of Clinical Oncology” EGFR-TKIs can cause unexpected skin, nail, and hair issues.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
1 citations
,
January 1998 in “International journal of cancer” Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
3 citations
,
June 2021 in “PLOS ONE” A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
2 citations
,
January 2004 in “Linchuang pifuke zazhi” ZD1839 can cause skin issues like acne and hair changes.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.